Development and evaluation of polyacrylamide microspheres loaded with phloretin and tantalum for transcatheter arterial embolization-Reference-Cited by-同舟云学术

Development and evaluation of polyacrylamide microspheres loaded with phloretin and tantalum for transcatheter arterial embolization

Published:2023 Issue:50 Volume:13 Page:35429-35434
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Li Liang¹^ORCID,Wang Mao Qiang¹²^ORCID,Duan Feng²^ORCID,Zhang Jin Long³^ORCID,Yuan Bing²^ORCID,Cui Bao⁴^ORCID,Zhang Heng¹⁵^ORCID,Yan Jie Yu²^ORCID

Affiliation:

1. Chinese PLA Medical School, Beijing 100853, PR China

2. Department of Interventional Radiology, Chinese PLA General Hospital, Beijing 100853, PR China

3. Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, PR China

4. Department of Interventional, Bethune International Peace Hospital, Shijiazhuang, 050082, PR China

5. Department of Radiology, National Clinical Research Center for Geriatric Diseases/Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China

Abstract

SEM results showed that polyacrylamide microspheres (PM) possess a significant porous structure. Following drug loading, the pores were filled with the drug. DSA results show that the X-ray opacity of PMs increases with increasing concentrations of nanosized tantalum powder.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/RA/D3RA05841G

Reference20 articles.

1. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence

2. TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis

3. Viable Hepatocellular Carcinoma Around Retained Iodized Oil After Transarterial Chemoembolization: Radiofrequency Ablation of Viable Tumor Plus Retained Iodized Oil Versus Viable Tumor Alone

4. Surgical and Locoregional Therapy of HCC: TACE